SCHEMBL23319910

SCHEMBL23319910

Cc1cncc(-c2ccc(Oc3[nH]nnc3C(=O)O)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
XDH P47989 7/20 0.44
CDK7 P50613 1/20 0.38
SLC22A12 Q96S37 3/20 0.37
MAP4K4 O95819 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA1 Q13131 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
HAO1 Q9UJM8 2/20 0.36
HCAR2 Q8TDS4 1/20 0.36
PIK3CG P48736 1/20 0.36
DHODH Q02127 1/20 0.35
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
ALPL P05186 1/20 0.34
CA9 Q16790 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
MAP3K8 P41279 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296970 0.86 ALPL (0.42) XDHPRKAG1PRKAA1PRKAB1HAO1
SCHEMBL23319930 0.84 XDH (0.37) XDHPRKAG1PRKAA1PRKAB1HAO1
SCHEMBL21312442 0.82 GAA (0.45) HAO1ALPL
SCHEMBL21296871 0.81 XDH (0.46) XDHSLC22A12MKNK1MKNK2PRMT5
SCHEMBL23319961 0.81 HAO1 (0.39) PRKAG1PRKAA1PRKAB1HAO1ALPL
SCHEMBL25465250 0.81 PRKAG1 (0.39) PRKAG1PRKAA1PRKAB1HAO1DHODH
SCHEMBL21296847 0.81 PRKAG1 (0.51) XDHPRKAG1PRKAA1PRKAB1HAO1
SCHEMBL23319995 0.81 HAO1 (0.46) PRKAG1PRKAA1PRKAB1HAO1ALPL
SCHEMBL23320006 0.81 HAO1 (0.46) PRKAG1PRKAA1PRKAB1HAO1ALPL
SCHEMBL21296854 0.81 HAO1 (0.44) PRKAG1PRKAA1PRKAB1HAO1MAP3K8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-11401246-B2 Triazole glycolate oxidase inhibitors Cantero Therapeutics, Inc. (US) 2022-08-02 US disclosed
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS VENTHERA, INC. 2021-12-30 US disclosed
EP-3817816-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS Orfan Biotech Inc. (US) 2021-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401246-B2 Triazole glycolate oxidase inhibitors XDH, DUOX1, PNPO XDH 1/4885CDK7 2504/4885SLC22A12 1915/4885
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO XDH 1/4885CDK7 2504/4885SLC22A12 1915/4885
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO XDH 1/4885CDK7 2504/4885SLC22A12 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.